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We investigated the association between prescribing
antimicrobial agents and antimicrobial resistance of
Streptococcus pneumoniae among children with acute oti-
tis media in southern Israel. During a 6-year period, all pre-
scriptions of a sample of ≈20% of Jewish and Bedouin
children <5 years of age were recorded and all pneumococ-
cal isolates from middle ear fluid were collected. Although
antimicrobial drug use was significantly higher in Bedouin
children, the proportion of S. pneumoniae isolates with
penicillin MIC >1.0 mg/mL was significantly higher in
Jewish children. In both populations, antimicrobial prescrip-
tions were markedly reduced over time, especially for peni-
cillins and erythromycin. In contrast, azithromycin
prescriptions increased from 1998 to 2001 with a parallel
increase in macrolide and multidrug resistance. Penicillin
resistance was associated with macrolide resistance.
These findings strongly suggest that azithromycin affects
increased antimicrobial resistance, including multidrug
resistance, in S. pneumoniae.
C
ommunity-acquired respiratory infections are the
main reason for prescribing antimicrobial agents in
young children (1). Antimicrobial drug use is a major con-
tributor to the emergence of resistance in respiratory
pathogens (2–5). Rates of antimicrobial drug use vary
between countries, leading to different rates of antimicro-
bial-resistant pathogens (6,7). Selection for resistant
organisms also depends on the class of antimicrobial agent
and pharmacokinetic and pharmacodynamic characteris-
tics of the drug (2,3,7,8). 
Acute otitis media is the most common microbial respi-
ratory tract infection in early childhood and a leading rea-
son for antimicrobial drug use in children in most
industrialized countries (9). Streptococcus pneumoniae
and  Haemophilus influenzae are the 2 most common
pathogens isolated from patients with acute otitis media
worldwide, comprising >75% of all microbial episodes
(10). During the last decade, an alarming increase in resist-
ance of S. pneumoniae to many antimicrobial agents has
been observed (11–14). In contrast, the prevalence of β-
lactamase production in H. influenzae is relatively stable. 
The dynamics of the relationship between antimicrobial
drug use and prevalence of resistance in S. pneumoniae has
not been systemically studied in children. We attempted to
determine the association between prescribing antimicro-
bial agents and resistance patterns of S. pneumoniae recov-
ered from middle ear fluid of children with acute otitis
media in southern Israel over a 6-year period. We hypoth-
esized that 1) the dynamics of antimicrobial resistance pat-
terns of S. pneumoniae causing acute otitis media are
associated with that of prescribing antimicrobial agents,
and 2) not all antimicrobial classes contribute equally to
resistance in this pathogen. 
Materials and Methods
Setting
In southern Israel (the Negev), Jewish and Bedouin
populations live side by side; the socioeconomic condi-
tions and the lifestyles of the 2 groups differ, but both
have access to the same medical services (both clinic and
hospitalization services). The Jewish population is mainly
urban, whereas the Bedouin population, formerly com-
posed of desert nomads, is in transition to a western
lifestyle (15). The 2 pediatric populations also differ in
disease patterns and rates. Hospitalization rates for respi-
ratory and other infectious diseases are higher among
Bedouin children (16,17). The only medical center pro-
viding hospital services to the Negev is the Soroka
University Medical Center, in which all children in the
area are born and treated.
Medical insurance in Israel is universal and provided
free of charge. Approximately 60% of Jewish children and
85%–90% of Bedouin children in the Negev are insured in
the largest health plan in Israel, the General Health
Insurance Plan. Antimicrobial treatment policies are iden-
tical in the 2 populations since drug formulations, prices,
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General Health Insurance Plan clinics. Criteria for referral
to a hospital are also similar, and no change in policy
occurred during the study period regarding referral to a
pediatric emergency room with a recommendation to per-
form tympanocentesis. 
The 7-valent pneumococcal conjugate vaccine (Preve-
nar, Wyeth-Lederle Vaccines, Pearl River, NY, USA) has
been licensed in Israel since 2004, but has not yet been
introduced into the country because of a supply shortage.
Thus, none of the children were vaccinated during the
study. 
Measuring Antimicrobial Drug Prescriptions
In the Negev region, 53 primary urban General Health
Insurance Plan clinics each care for a minimum of 3,000
members. Data were gathered from the 7 largest pediatric
primary care clinics where all prescriptions were comput-
erized during all study years. Five clinics, caring for a
yearly average population of 6,163 children <5 years age,
were located in urban Jewish centers; 2 clinics, caring for
a yearly average population of 6,636 children <5 years of
age, were located in Bedouin towns. This accounts for
≈20% of the region’s children in this age group. Twenty-
five to 30 physicians treated children at these clinics. All
computerized data regarding prescriptions were generated
from the economic department of the General Health
Insurance Plan in southern Israel. All antimicrobial drug
prescriptions for outpatient children <5 years of age were
recorded from 1998 through 2003 and grouped as follows:
penicillins (amoxicillin, amoxicillin-clavulanate, and phe-
noxymethyl penicillin); cephalosporins (cefaclor,
cephalexin monohydrate, and cefuroxime-axetil); erythro-
mycin (stearate or ethyl-succinate); and azithromycin.
Internal data analysis showed no differences in prescribing
antimicrobial agents between the different clinics within
each ethnic group.
Microbial Isolates 
All middle ear fluid specimens from patients treated at
the Soroka University Medical Center pediatric emergency
room and patients hospitalized with acute otitis media, and
>90% of the middle ear fluid specimens obtained by oto-
laryngologists in the community, are sent for culture to the
Clinical Microbiology Laboratory of this medical center,
the only microbiology laboratory in the Negev. Two thirds
of the aspirates were obtained at this medical center (40%
in the emergency room and another 26% in pediatric
wards). Patients at this center with acute otitis media and
bulging tympanic membrane undergo tympanocentesis,
which is done by an otolaryngologist. In the outpatient
clinics (approximately one third of the patients), tympa-
nocentesis is typically carried out in patients with recurrent
or nonresponsive acute otitis media. A small proportion of
middle ear fluid aspirates were obtained as part of double
tympanocentesis studies. All S. pneumoniae isolates
obtained from the middle ear fluid of children with
episodes of acute otitis media from 1999 through 2003 that
were processed at Soroka University Medical Center were
included.
An episode was defined as a pathogen-free interval of
>30 days between isolations for the same serotype or by
any interval for different serotypes. Only 1 isolate was
counted per episode; if the same strain was isolated from
both ears, 1 of the 2 was randomly selected.
Microbiologic Analysis 
Swabs were placed in MW173 Amies transport medi-
um (Transwab, Medical Wire and Equipment, Potley, UK),
plated immediately on trypticase agar media containing
5% sheep blood and 5 µg/mL of gentamicin, and incubat-
ed aerobically at 35°C for 48 h. Presumptive identification
of S. pneumoniae was based on the presence of α-hemoly-
sis and inhibition by optochin and was confirmed by slide
agglutination (Phadebact, Pharmacia Diagnostics,
Uppsala, Sweden). Serotyping was conducted by using the
quellung reaction with reagents from Statens Serum
Institut (Copenhagen, Denmark) (18). Susceptibility of S.
pneumoniae to sulfamethoxazole, tetracycline, erythromy-
cin, clindamycin, and chloramphenicol was determined by
using the Kirby-Bauer disk diffusion method and interpret-
ed according to the National Committee for Clinical
Laboratory Standards (19). Macrolide resistance was
reported as erythromycin resistance. Isolates exhibiting
inhibition zones ≤19 mm with a 1-µg oxacillin disk were
further tested by Etest (PDM Epsilometer, AB Biodisk,
Solna, Sweden) for penicillin (20). Isolates with a peni-
cillin MIC >0.1 µg/mL were considered nonsusceptible to
penicillin. Isolates with a penicillin MIC >1.0 µg/mL were
analyzed separately. Isolates resistant to >3 antimicrobial
classes were considered multidrug resistant.
Statistical Analysis
Statistical analysis was done with SPSS (Chicago, IL,
USA) 12.0 software for Windows. The chi-square test was
used to compare the distribution of categoric data. Linear
regression analysis with the Pearson correlation coefficient
was done to test the linear increase or decrease of antimi-
crobial prescription rates. A similar procedure was per-
formed for exponential increases or decreases in
prescription rates, but variables were tested after logarith-
mic transformation. Comparisons of mean yearly differ-
ences in antimicrobial prescription rates between Bedouin
and Jewish children were done using the paired samples
t test. A p value <0.05 was considered significant. 
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Prescribing of Antimicrobial Agents
A total of 236,466 prescriptions (149,589 for Bedouin
and 86,877 for Jewish children) were recorded in the 7
clinics, which represented 12,799 child-years in children
<5 years of age (Table). Overall prescribing of antimicro-
bial agents to Bedouin children was higher (mean ± SD
3.79 ± 0.4 prescriptions per child-year) than to Jewish chil-
dren (2.37 ± 0.3 prescriptions per child-year). This repre-
sents a mean difference of 1.41 prescriptions per
child-year (p<0.001).
As a group, penicillins were the most frequently pre-
scribed agents and accounted for 80.6% (120,514/149,589)
of prescriptions for Bedouin and 80.4% (69,872/86,877)
for Jewish children (Table and Figure 1). The cephalo-
sporin group ranked second in Bedouin children (12.5% of
all prescriptions), and azithromycin ranked second in
Jewish children (10.4% of all prescriptions). Significantly
more amoxicillin (1.53-fold), amoxicillin-clavulanate
(2.10-fold), cephalosporins (3.04-fold), and erythromycin
(1.44-fold) were prescribed for Bedouin than for Jewish
children. Jewish children received more prescriptions for
phenoxymethyl penicillin (1.20-fold) and azithromycin
(1.41-fold) than Bedouin children. All differences between
prescription rates of Bedouin and Jewish children were
significant (Table).
A significant decrease in total antimicrobial prescrip-
tions was noted with time (Figure 1). In Bedouin children,
total antimicrobial prescription rate was reduced 29% from
4,389 per 1,000 children in 1998 to 3,106 per 1,000 chil-
dren in 2003 (p = 0.038, r = –0.835 for exponential
decrease). In Jewish children, total prescription rate was
reduced 30% from 2,949 per 1,000 children in 1998 to
2,079 per 1,000 children in 2003 (p = 0.014, r = –0.902 for
exponential decrease). The decrease in total antimicrobial
prescription rate in both populations was caused mostly by
a reduction in the prescription rate of penicillins. The
erythromycin prescription rate decreased sharply in both
populations. In Bedouin children, the rate was reduced
76% from 181 prescriptions per 1,000 children in 1998 to
44 per 1,000 children in 2003 (p<0.001, r = –0.984 for
exponential decrease); in Jewish children, the rate was
reduced 81% from 149 prescriptions per 1,000 children in
1998 to 29 per 1,000 children in 2003 (p = 0.002; r =
–0.963 for exponential decrease). 
Azithromycin was introduced in Israel in 1998. The
prescription rate of this drug increased dramatically to 310
prescriptions per 1,000 Bedouin children (p = 0.04, r =
0.996 for linear increase) and 357 prescriptions per 1,000
Jewish children (p = 0.011, r = 0.989 for linear increase) in
2001. Thereafter, a sharp decrease in azithromycin pre-
scription rate (a 51% decrease to 152/1,000) was noted in
Bedouin children (p = 0.024, r = –0.999 for linear decrease
from 2001 to 2003). In Jewish children, the azithromycin
prescription rate decreased 31%, but this did not reach sta-
tistical significance (p = not significant for linear decrease
from 2001 to 2003). No significant change in the
cephalosporin prescription rate was observed in these pop-
ulations.
Acute Otitis Media Episodes
A total of 11,311 episodes of acute otitis media requir-
ing tympanocentesis were recorded in the region during
the study period. At least 1 pathogen was isolated in 59%
(6,678/11,311) of the episodes. 
S. pneumoniae Acute Otitis Media Episodes 
A total of 3,651 S. pneumoniae acute otitis media
episodes were recorded: 39% (1,425/3,651) of the isolates
were obtained from Jewish children and 61%
(2,223/3,651) from Bedouin children. The ethnicity of the
child was not recorded for 3 isolates. In 89% (3,258/3,651)
of the children, a complete history regarding previous
episodes of acute otitis media and antimicrobial treatment
was available. Twenty-nine percent (978/3,396) of the
children had had 1–3 episodes of acute otitis media and
36% (1,225/3,396) had >3 episodes of acute otitis media in
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episodes occurred in children who had already undergone
tympanocentesis. A total of 24% (809/3,373) of the chil-
dren were receiving antimicrobial agents at the time of
tympanocentesis, and 36% (1,231/3,373) had received
antimicrobial agents in the preceding month. No major dif-
ferences in the proportions of these characteristics were
seen within each ethnic group.
S. pneumoniae Antimicrobial Resistance Patterns
A total of 98% (3,600/3,651) of S. pneumoniae isolates
were available for antimicrobial susceptibility testing.
Penicillin-nonsusceptible isolates constituted most of the
isolates (62% [869/1,399] and 64% [1,418/2,201] of all
isolates in Jewish and Bedouin children, respectively)
without a significant change in time or in the relative pro-
portions between the 2 populations (Figure 2). However,
resistance patterns differed significantly. Among Jewish
children, 52%–67% of all penicillin-nonsusceptible iso-
lates had a penicillin MIC >1.0 µg/mL each year (532 of
all 1,399 isolates, 38%). Among Bedouin children, only
30%–40% of the nonsusceptible isolates (528 of all 2,201
isolates, 24%) had a penicillin MIC >1.0 µg/mL each year
(p<0.001). Thus, despite the reduction in the prescription
rates of penicillins in both populations, no parallel
decrease in penicillin nonsusceptiblility was observed.
Furthermore, the highest penicillin MIC values were con-
tinuously observed in Jewish children, for whom the low-
est penicillin prescription rates were recorded.
Erythromycin resistance was more common in Jewish
(25%, 356/1,425) than in Bedouin children (16%,
355/2,221) (p<0.001). In Bedouin children, rates of eryth-
romycin resistance increased significantly from 1999
through 2002, from 9% (41/456) to 21% (93/440), respec-
tively (p<0.001). In Jewish children, erythromycin resist-
ance decreased from 23% (61/261) in 1999 to 18%
(48/270) in 2000 (p = 0.01). Thereafter, the proportion of
resistant isolates increased as well, reaching 29% (84/291)
in 2002 (p = 0.02). Erythromycin resistance did not
increase in either population during 2003. In 2003, 17%
(63/375) and 27% (90/336) of isolates in Bedouin and
Jewish children, respectively, were erythromycin-resistant
(Figure 3). The multidrug-resistance pattern paralleled that
of erythromycin resistance in each population. Thus, both
erythromycin and multidrug resistance increased in paral-
lel with the increase in the azithromycin prescription rate,
and resistance tended to decrease with the change in this
rate. Furthermore, the population with the highest
azithromycin prescription rate also had the highest rates of
erythromycin resistance.
Penicillin MIC values were not equally distributed
among erythromycin-susceptible and erythromycin-resist-
ant S. pneumoniae isolates (Figure 4). In both Jewish and
Bedouin children, the proportion of penicillin-susceptible
S. pneumoniae was greater in erythromycin-susceptible
isolates, and the proportion of isolates with a penicillin
MIC >1.0 µg/mL was greater in erythromycin-resistant S.
pneumoniae (p<0.001 for each comparison).
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Figure 1. Antimicrobial drug prescription rates for Bedouin and
Jewish children <5 years of age in southern Israel from 1998
through 2003. Amoxi, amoxicillin; Amoxi-clav, amoxicillin-clavu-
lanate; Pen, phenoxymethyl penicillin; Azithro, azithromycin;
Ceph, cephalosporins (cefazolin, cefaclor, cephalexin monohy-
drate, and cefuroxime-axetil); Ery, erythromycin.Discussion
We attempted to determine whether antimicrobial pre-
scription patterns were associated with resistance patterns
among S. pneumoniae isolates from young children with
acute otitis media in 2 populations treated by the same
medical system, but living in separate communities with
different lifestyles. We used prescription rates of ≈20% of
the children <5 years of age in each population and a large
collection of middle ear fluid S. pneumoniae isolates
obtained from these 2 populations during the same time
period. This unique opportunity enabled us to not only
relate resistance dynamics to prescriptions dynamics for
each population, but also to observe whether differences in
antimicrobial prescription rates between populations could
explain some of the differences in antimicrobial resistance
patterns.
The association of azithromycin prescriptions with
antimicrobial resistance patterns among S. pneumoniae
isolated from middle ear fluid is noteworthy for several
reasons. First, the prescription rate for azithromycin was
the only one that was higher among Jewish children than
among Bedouin children. Second, the azithromycin pre-
scription rate pattern closely paralleled both macrolide and
multidrug resistance in each population. Third, higher
penicillin MIC values were associated with macrolide
resistance, which explained, at least in part, the higher
rates of S. pneumoniae isolates from middle ear fluid with
a penicillin MIC >1.0 µg/mL among Jewish children who
received relatively fewer amoxicillin (with or without
clavulanate) prescriptions than Bedouin children who
received more amoxicillin prescriptions (with or without
clavulanate).
The distinct pattern of reducing total antimicrobial drug
prescriptions that resulted from reducing prescribed peni-
cillins, although azithromycin use increased, was reported
in other regions, including the United States (21,22) and
western Europe (23). The pattern of reduced antimicrobial
drug use could be the result of campaigns such as those
conducted in the United States following the initiative by
the Centers for Disease Control and Prevention for the
judicious use of antimicrobial drugs, which recommended
the first-line use of amoxicillin to treat acute otitis media
(21) (http://www.cdc.gov/drugresistance/community/files/
ads/Otitispa.pdf). However, the increase in azithromycin
prescriptions, along with a reduction in penicillin prescrip-
tions, could be partly the result of commercial promotion
campaigns for the use of azithromycin, which were
launched in parallel with campaigns to reduce the overall
use of antimicrobial agents.
The increase in the azithromycin prescription rate in
our study, as in Europe and North America, is partly attrib-
utable to the properties that make this drug an attractive
agent for children. The long half-life of azithromycin
(<72 h) (24) makes a convenient dose regimen of once a
day for ≤5 days. However, it is eliminated very slowly and
remains at subinhibitory concentrations in tissues of per-
sons with pneumococcal infections. Subinhibitory concen-
trations of antimicrobial agents favor the selection of
resistant mutants. This has been shown in vitro for S. pneu-
moniae exposed to subinhibitory macrolide concentrations
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Figure 2. Proportions of penicillin-resistant Streptococcus pneu-
moniae isolated during episodes of acute otitis media in Bedouin
and Jewish children <5 years of age in southern Israel from 1999
through 2003. Pen-MIC, penicillin MIC (µg/mL); Pen-NS, penicillin-
nonsusceptible.(25). In a clinical trial, children treated with azithromycin
harbored significantly more resistant strains in their oral
flora than those who randomly received other macrolides.
After 6 weeks, 85% still had macrolide-resistant organisms
(26). In European countries, the increase in prescriptions
of long-acting macrolides resulted in selection for
macrolide resistance in S. pneumoniae (27,28). 
Our finding that azithromycin prescriptions were associ-
ated with S. pneumoniae multidrug resistance was notewor-
thy. The ability of certain antimicrobial agents to promote
resistance to other drug classes has been previously report-
ed. Several studies showed that use of long-acting
macrolides was an important factor in increasing penicillin
resistance in a given community (29,30). This could
explain the higher rates of resistant S. pneumoniae with
MIC  >1.0  µg/mL in Jewish than in Bedouin children,
despite significantly lower prescription rates for penicillins,
but significantly higher prescription rates for azithromycin.
This pattern of increasing penicillin and macrolide resist-
ance in association with increased prescribing of
azithromycin was also observed in the United States, where
it was predicted that in the absence of pneumococcal con-
jugate vaccine, by 2004 ≈40% of all S. pneumoniae isolates
would be resistant to both penicillin and macrolides and
that the increased rate would be exponential (31).
The differential effect of azithromycin versus amoxi-
cillin on nasopharyngeal carriage of antimicrobial-resist-
ant S. pneumoniae in patients was demonstrated in a study
conducted in southern Israel. In this study, carriage of both
macrolide- and multidrug-resistant S. pneumoniae marked-
ly decreased in children with acute otitis media receiving
amoxicillin-clavulanate, but increased markedly in those
receiving azithromycin (32). This differential effect lasted
more than 1 month. 
Our study has 3 limitations. First, the factors contribut-
ing to differences in antimicrobial drug use between the 2
populations could not be controlled. Antimicrobial drug
prescriptions could not be matched with individual use. In
addition, potential confounders such as family structure
and daycare exposure could not be assessed. The higher
prescription rate for antimicrobial agents in Bedouin chil-
dren could be explained by differences in accessibility to
healthcare facilities. However, since there is no financial
burden for healthcare in Israel and all clinics belong to the
same health plan, acute otitis media is unlikely to be treat-
ed differently in either population. The similar reduction in
antimicrobial drug prescriptions in both populations sug-
gests that no difference in prescribing policies existed
between the 2 populations. Lower socioeconomic status
and overcrowding in the Bedouin population, which led to
a higher rate of respiratory illness in this group (16,17),
may explain the difference in rates of antimicrobial drug
prescriptions. 
Second, S. pneumoniae were obtained only from chil-
dren with acute otitis media. However, S. pneumoniae is
part of the normal nasopharyngeal flora and is exposed to
antimicrobial agents regardless of the diagnosis for which
the agent was prescribed. Therefore, we believe that the
effect of prescribing antimicrobial drugs in the community
on resistance patterns of S. pneumoniae isolated from
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Figure 3. Proportions of erythromycin-resistant and multidrug-
resistant Streptococcus  pneumoniae isolated during episodes of
acute otitis media in Bedouin and Jewish children <5 years of age
in southern Israel from 1999 through 2003. Ery-R, erythromycin
resistance; MDR, multidrug resistance (resistance to >3 antimicro-
bial classes).middle ear fluid represents the effect on the entire spec-
trum of S. pneumoniae disease.
Third, this was not an intervention study; therefore, we
could not demonstrate unequivocally the causative effect
of azithromycin use on macrolide and multidrug resistance
in S. pneumoniae. However, the association demonstrated
in this study, together with published data, strongly suggest
such a causative effect.
The introduction of the 7-valent pneumococcal conju-
gate vaccine to infant and toddler immunization programs
in the United States was associated with a reduction in
invasive diseases (33,34) and acute otitis media (35,36)
caused by antibiotic-resistant S. pneumoniae. However,
persistence of antimicrobial resistance within vaccine and
nonvaccine serotypes (37–40) suggests that vaccine alone
may not reduce antimicrobial resistance, and that if the use
of antimicrobial drugs is not controlled, the ability of the
pneumococcal conjugate vaccine to reduce antimicrobial-
resistant S. pneumoniae may be only transient. 
During the last 2 years of this study, prescription rates
were reduced in both populations. This reduction could be
partly explained by efforts of pediatric infectious diseases
specialists to educate pediatricians and family physicians in
the study area to reduce use of antimicrobial drugs, espe-
cially oral use of cephalosporins and macrolides-azalides.
However, this effect may not be the main reason for this
decrease. A decrease in macrolide and multidrug resistance
of S. pneumoniae observed in the last year of this study may
indicate that the effect of azithromycin use on antimicrobial
resistance is reversible. Continuous monitoring of antimi-
crobial prescriptions and resistance in respiratory
pathogens should help determine if a further decrease in
azithromycin prescriptions would be followed by a further
decrease in antimicrobial resistance of S. pneumoniae.
In conclusion, azithromycin prescriptions were associat-
ed with macrolide, penicillin, and multidrug resistance
among S. pneumoniae isolated from the middle ear fluid of
children with acute otitis media. Such an association was
not found with amoxicillin (with or without clavulanate)
prescriptions. When promoting judicious use of antimicro-
bial drugs, selective reduction in prescribing specific
antimicrobial drugs such as azithromycin should be empha-
sized, in addition to total reduction in antimicrobial use.
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Figure 4. Distribution of penicillin MICs (µg/mL) in erythromycin-
susceptible and erythromycin-resistant Streptococcus pneumoni-
ae isolated during episodes of acute otitis media in Bedouin and
Jewish children <5 years of age in southern Israel from 1999
through 2003. P was calculated for the difference in overall distri-
bution of penicillin MICs between erythromycin-susceptible and
erythromycin-resistant isolates, as well as for difference in relative
contribution of isolates with MICs >1.0 µg/mL to both groups
(p<0.001, Ery-S versus Ery-R in both Bedouin and Jewish chil-
dren). Ery-S, erythromycin susceptible; Ery-R, erythromycin resist-
ant; Pen-MIC, penicillin MIC.References
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